Evaluating the elimination of iCasp9-IL15 CAR-T cells using photosensitizers AP20187 in vitro

Can Van Mao, Le Duy Cuong

Nội dung chính của bài viết

Tóm tắt

This study was conducted to evaluate the ability to eliminate iCasp9-IL15 Chimeric Antigen Receptor-T (CAR-T) cells using the photosensitizers AP20187 in vitro. Peripheral blood mononuclear cells (PBMC) were activated with Dynabeads Human T-Activator CD3/CD28 and IL-2 to optimize the concentration of the antibiotic blasticidin for screening iCasp9-IL15 CAR-T cells. iCasp9-IL15 CAR-T cells after proliferation with 1D2 artificial antigen-presenting cells, were screened using blasticidin. Subsequently, the iCasp9 suicide gene of these cells was activated at various concentrations of AP20187 photosensitizer. The results showed that after 5 days of culture, a blasticidin concentration of 15.0 µg/mL was used to screen iCasp9-IL15 CAR-T cells (activated, non-transformed PBMC showed > 95% cell death). The proportion of iCasp9-IL15 cells after blasticidin screening reached approximately 75%. Using AP20187 at the concentration of 20 nM resulted in almost complete elimination of iCasp9-IL15 CAR-T cells (survival rate: 2.14%). So, iCasp9-IL15 CAR-T cells can almost be eliminated by AP20187 at a concentration of 20 nM in case of high toxicity during treatment.

Chi tiết bài viết

Tài liệu tham khảo

1. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25.
2. June CH, Sadelain M. Chimeric antigen receptor therapy. New England Journal of Medicine. 2018;379(1):64-73.
3. Bangolo A, Amoozgar B, Mansour C, et al. Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. Cancers (Basel). 2025;17(2):282.
4. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664-679.
5. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160-1170.
6. Bento FM, Takeshita D, Sacramento CB, et al. Over expression of the selectable marker blasticidin S deaminase gene is toxic to human keratinocytes and murine BALB/MK cells. BMC Biotechnol. 2004;4:1-10.
7. Buck JM, Bártulos CR, Gruber A, et al. Blasticidin-S deaminase, a new selection marker for genetic transformation of the diatom Phaeodactylum tricornutum. PeerJ. 2018;6:e5884.
8. Asoshina M, Myo G, Tada N, et al. Targeted amplification of a sequence of interest in artificial chromosome in mammalian cells. Nucleic Acids Res. 2019;47(11):5998-6006.
9. Hanswillemenke A, Stafforst T. Protocols for the generation of caged guideRNAs for light-triggered RNA-targeting with SNAP-ADARs. Methods in Enzymology. Elsevier; 2019:47-68.
10. Zhou X, Di Stasi A, Brenner MKJGToSCM. iCaspase 9 suicide gene system. Methods Mol Biol. 2015:87-105.
11. Gargett T, Brown MPJFip. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
12. Yu S, Yi M, Qin S, et al. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18:1-13.
13. Liu Z, Chen O, Wall JBJ, et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep. 2017;7(1):2193.